Alpha-GPC vs CDP-Choline: Evidence-Based Comparison for Cognitive Support
"In a crossover comparison in 12 healthy volunteers, single 1,000 mg intramuscular doses raised mean free plasma choline by about 25.8 micromol/L with alpha-GPC versus 13.1 micromol/L with citicoline - the most frequently cited head-to-head measurement of the two compounds."
Gatti G, Barzaghi N, Acuto G, Abbiati G, Fossati T, Perucca E. Int J Clin Pharmacol Ther Toxicol. 1992;30(9):331-335 (verified finding, not a verbatim quotation)
Alpha-GPC and CDP-choline (citicoline) are the two most widely studied supplemental choline donors in cognitive research. Both raise circulating choline, both supply substrate for acetylcholine synthesis, and both appear in clinical trials of memory, attention and neuroprotection. Their chemistry, pharmacokinetics and evidence bases differ enough that choosing between them means understanding what each compound actually does once ingested.
This brief compares alpha-GPC and CDP-choline across bioavailability, mechanisms, clinical evidence, dosing and practical formulation considerations. Where the published evidence is thin, mixed or drawn from patient populations rather than healthy adults, the text says so rather than smoothing it over.
What Are Alpha-GPC and CDP-Choline?
Alpha-GPC (L-alpha-glycerylphosphorylcholine) is a choline-containing phospholipid present in brain tissue and, in small amounts, in foods such as dairy. With a molecular weight of 257.22 g/mol it is about 41% choline by weight, among the highest choline contents of the common supplemental forms, and it crosses the blood-brain barrier [1]. Supplemental alpha-GPC is usually produced from soy or sunflower lecithin; raw material is frequently supplied as a 50% blend on a carrier, so a label reading "alpha-GPC 50%" describes ingredient concentration, not choline content. Once ingested, alpha-GPC is hydrolysed and releases choline that can be used for acetylcholine and membrane phospholipid synthesis [1].
CDP-choline (cytidine-5'-diphosphocholine), sold as citicoline, is an endogenous intermediate in phosphatidylcholine biosynthesis. Oral absorption is close to complete; the molecule is hydrolysed in the gut wall and liver into its choline and cytidine components, which are then used to resynthesise CDP-choline in tissue [2]. At 488.32 g/mol it is a substantially larger molecule than alpha-GPC, so it carries less choline per milligram [2].
One species difference is worth noting. In rodents, oral citicoline raises plasma cytidine; in humans it does not. When healthy volunteers took 500, 2,000 or 4,000 mg of oral CDP-choline, plasma cytidine was not reliably detectable, while plasma uridine rose by roughly 70-90% after 500 mg and 100-120% after 2,000 mg. The circulating substrates through which oral citicoline reaches brain membrane phosphatide synthesis in humans therefore appear to be choline and uridine, not cytidine [3]. The practical point stands - citicoline supplies both a choline moiety and a pyrimidine moiety, which alpha-GPC does not - but the human pathway runs through uridine.
What Are Alpha-GPC and CDP-Choline Used For?
Both compounds are used to support cognitive function. Much of the clinical literature, however, comes from prescription use in older patients with dementia or stroke in Europe and Asia, not from healthy supplement users, and that context limits how far the findings can be generalised.
- Memory and age-related cognitive decline: Alpha-GPC has been examined in dementia and cerebrovascular cognitive decline; an analysis of published clinical data covering 13 trials and 4,054 patients reported consistently positive cognitive and behavioural findings while calling for confirmation in studies meeting modern methodological standards [4]. CDP-choline has been reviewed by Cochrane in older people with cognitive impairment from chronic cerebral disorders [5].
- Attention: Citicoline at 250 or 500 mg daily for 28 days improved attention and psychomotor speed versus placebo in 75 healthy adolescent males - a healthy-volunteer study, not a trial in diagnosed attention disorders [6]. Alpha-GPC is more often used in nootropic stacks aimed at acute performance.
- Neuroprotection research: Citicoline has been tested extensively in acute ischaemic stroke, with a positive pooled analysis of earlier trials [7] but a null result in the largest randomised trial [8]. Alpha-GPC has no comparable stroke trial programme.
- Exercise performance: Alpha-GPC has preliminary, inconsistent data on force production and growth hormone response [9][10]. CDP-choline has no equivalent sports-performance dataset.
Bioavailability and Pharmacokinetics
Head-to-head pharmacokinetic data are scarce. The most frequently cited comparison is a crossover study in 12 healthy volunteers who received single 1,000 mg intramuscular doses of each compound on separate occasions: free plasma choline rose with a similar time course after both, but the mean increase was roughly twice as large after alpha-GPC (about 25.8 micromol/L) as after citicoline (about 13.1 micromol/L) [11]. That study used injections, not capsules, and no equivalent oral head-to-head trial has been published - so the widespread claim that alpha-GPC delivers more choline per oral milligram rests mainly on its higher choline content by weight rather than on a direct oral comparison [1][11].
What is well documented for citicoline is a dose-related and relatively prolonged rise in plasma choline. In healthy volunteers, peak values and areas under the curve increased with dose, and plasma choline stayed significantly elevated for about 5, 8 and 10 hours after 500, 2,000 and 4,000 mg respectively, with plasma uridine elevated for 5-6 hours [3]. Oral citicoline is absorbed almost completely, which is why oral and intravenous bioavailability are considered broadly similar [2].
Mean increases in free plasma choline after a single 1,000 mg intramuscular dose were about 25.8 micromol/L for alpha-GPC and 13.1 micromol/L for citicoline in 12 healthy volunteers. No oral head-to-head comparison has been published.
The practical implication is modest rather than dramatic: alpha-GPC dosing delivers more choline per milligram and is the form more often used before a task or training session, while citicoline's documented multi-hour choline and uridine elevation fits once-daily use [1][3].
Clinical Evidence and Mechanisms
Alpha-GPC
Most alpha-GPC trials were conducted in older adults with cognitive decline. Parnetti and colleagues analysed published clinical data from 13 trials involving 4,054 patients with dementia of degenerative or vascular origin and reported consistent improvements on cognitive and behavioural measures with choline alphoscerate, typically at 1,200 mg/day, while noting that most trials were old and that the findings needed confirmation in better-designed studies [4]. This was a narrative analysis of published data, not a pooled meta-analysis, and it does not establish alpha-GPC as a treatment for any disease.
A 2025 systematic review and meta-analysis compared the two compounds directly in dementia populations, pooling three randomised controlled trials with 358 participants treated for 90 days. Alpha-GPC was associated with better overall clinical status on the Sandoz Clinical Assessment-Geriatric scale than citicoline (weighted mean difference -3.92; 95% CI -7.41 to -0.42), with no significant difference between the groups on memory or word fluency testing and similar dropout rates (9.4% versus 6.7%) [12].
In younger, healthy adults the evidence is thin and mixed. In 48 college-aged men randomised to 250 mg alpha-GPC, 500 mg alpha-GPC, 200 mg caffeine or placebo for seven days, there were no group differences in isometric strength or psychomotor vigilance, although countermovement jump peak velocity and power did differ between groups, favouring the 250 mg dose; serum free choline rose by 132% and 59% above placebo in the 500 mg and 250 mg groups [10]. A separate placebo-controlled study in healthy volunteers using 400 mg/day for two weeks reported improved self-rated motivation, with no change in anxiety [13]. An often-quoted conference abstract found peak bench-press force 14% greater after a single 600 mg dose of alpha-GPC than placebo (933 +/- 89 N versus 818 +/- 77 N; P < 0.02), with peak power only trending higher [9]. That abstract has not been published as a peer-reviewed paper or independently replicated, so it should be read as preliminary.
CDP-Choline
A Cochrane review of 14 randomised, double-blind, placebo-controlled trials in older people with cognitive impairment from chronic cerebral disorders found some evidence of benefit for memory and behaviour over the short to medium term, no clear benefit for attention, and good tolerability; the reviewers emphasised heterogeneity in dose, population and outcome measures, and that all but one trial lasted three months or less [5]. Mechanistically, citicoline supplies choline for acetylcholine synthesis and uridine for membrane phosphatide synthesis in humans [3].
In acute ischaemic stroke, an individual-patient-data pooling analysis of four randomised placebo-controlled trials (1,372 patients; 789 on citicoline at 500-2,000 mg/day, 583 on placebo) reported that oral citicoline started within 24 hours of onset increased the probability of complete recovery at three months in moderate-to-severe stroke, with safety similar to placebo [7]. The subsequent ICTUS trial, the largest in the programme, randomised 2,298 patients and was stopped for futility: global recovery was essentially identical between groups (odds ratio 1.03; 95% CI 0.86-1.25; P = 0.364), and the authors concluded citicoline was not efficacious in moderate-to-severe acute ischaemic stroke [8]. Taken together the stroke literature is best described as mixed and, in any case, concerns acute hospital treatment rather than supplement use.
In healthy adolescents, 75 males aged 13-18 received 250 mg or 500 mg citicoline or placebo for 28 days; the citicoline groups showed improved attention (P = 0.02) and increased psychomotor speed (P = 0.03), with higher weight-adjusted doses associated with better accuracy and fewer commission errors [6]. This was a healthy-volunteer trial; it does not support claims about diagnosed attention disorders.
| Feature | Alpha-GPC | CDP-Choline |
|---|---|---|
| Choline content | ~41% by weight [1] | Less per mg (larger molecule, 488.32 g/mol) [2] |
| Head-to-head plasma choline (1,000 mg IM) | +25.8 micromol/L [11] | +13.1 micromol/L [11] |
| Uridine delivery in humans | No | Yes [3] |
| Comparative dementia trials | Favoured on SCAG global score [12] | Comparable on memory and word fluency [12] |
| Healthy-adult trials | Limited, mixed [10][13] | Positive 28-day trial in adolescent males [6] |
| Acute stroke trials | No comparable data | Positive pooled analysis [7]; null large RCT [8] |
| Exercise performance | Preliminary, unreplicated [9][10] | No published data |
| Doses used in trials | 250-1,200 mg/day [4][10][13] | 250-2,000 mg/day [6][7] |
Clinical Considerations
Where Alpha-GPC May Fit
- Acute, task-linked use: Alpha-GPC's higher choline content per milligram and rapid rise in plasma choline make it the form usually chosen before a task or training session, though the supporting human data are limited [1][11].
- Exercise contexts: What little comparative sports data exist involve alpha-GPC rather than citicoline, and those findings are preliminary and not consistently replicated [9][10].
- Choline delivery per milligram: At roughly 41% choline by weight, alpha-GPC supplies more choline per milligram than citicoline [1][2].
Where CDP-Choline May Fit
- Sustained daily use: Plasma choline remains elevated for several hours after a single oral dose, alongside a parallel rise in uridine [3].
- Membrane-substrate rationale: Citicoline supplies both choline and (via uridine) substrate for phosphatidylcholine synthesis, a mechanism alpha-GPC does not provide [2][3]. This is a mechanistic rationale, not demonstrated clinical superiority.
- Depth of clinical study: Citicoline has been studied in large randomised trials, including stroke programmes, which gives a comparatively large safety dataset even where efficacy results were null [7][8].
Safety and Tolerability
Both compounds are generally well tolerated at the doses used in research. Oral alpha-GPC at 1,200 mg/day for six months has been reported without serious adverse effects [13], and citicoline has been given at 500-2,000 mg/day in stroke trials with a safety profile similar to placebo [7][8]. Reported side effects are mostly mild - gastrointestinal upset, headache. Interactions with cholinergic medications such as acetylcholinesterase inhibitors have not been well characterised, so anyone taking them should speak with a clinician before adding a choline donor.
One signal deserves attention. A retrospective cohort study using South Korea's National Health Insurance Service database followed about 12 million adults aged 50 or older and found that alpha-GPC users (n = 108,877) had a higher 10-year risk of total stroke than non-users (adjusted hazard ratio 1.46; 95% CI 1.43-1.48) and of ischaemic stroke (adjusted hazard ratio 1.36; 95% CI 1.33-1.39) [14]. This is an observational study and cannot establish causation; confounding by indication is plausible, since alpha-GPC is prescribed in Korea to people who already have cerebrovascular risk. Until prospective data clarify the question, people with cerebrovascular disease may reasonably prefer citicoline or dietary choline sources over long-term high-dose alpha-GPC, and discuss the choice with a clinician.
How to Choose Between Alpha-GPC and CDP-Choline
- Consider alpha-GPC for episodic, task-linked use when the goal is the largest choline delivery per milligram; the direct comparison supporting this used intramuscular dosing, so treat it as suggestive rather than settled [1][11].
- Consider CDP-choline for steady daily use, particularly if the uridine-linked membrane rationale matters to you, or if you are older or have vascular risk factors and want the compound with the larger randomised safety dataset [3][7][8].
- Read the standardisation carefully: alpha-GPC raw material is commonly 50% on a carrier, so 200 mg of a 50% blend supplies 100 mg of alpha-GPC - roughly 41 mg of choline [1]. Citicoline is normally sold as the pure compound.
- Match the dose to the evidence: trials have used 250-1,200 mg/day alpha-GPC and 250-2,000 mg/day citicoline [4][6][7][10][13]. Doses below 200 mg are common in nootropic stacks but have not been tested on their own.
- Think about the whole formula: multi-ingredient cognitive products often pair a moderate dose of alpha-GPC with ingredients such as phosphatidylserine or L-tyrosine. That is a formulation strategy, not a tested combination, so judge each ingredient on its own evidence.
Conclusion
Alpha-GPC and CDP-choline are both well-studied choline donors with different profiles. Alpha-GPC carries more choline per milligram and produced a larger rise in free plasma choline in the one published head-to-head comparison, which used intramuscular dosing [1][11]. Citicoline produces a multi-hour elevation of plasma choline and uridine and has been tested in far larger randomised trials, with mixed results [3][7][8]. A 2025 meta-analysis of three head-to-head trials in dementia patients favoured alpha-GPC on a global clinical scale but found no difference on memory testing [12]. Neither compound is clearly superior for healthy adults seeking cognitive support, and neither should be used to treat or prevent any disease.
If you are looking for a cognitive formula that includes a moderate dose of alpha-GPC within a broader stack - alongside L-tyrosine, phosphatidylserine, ashwagandha, rhodiola and omega-3s - Focase Cognition Support provides 200 mg alpha-GPC at 50% standardisation, which supplies 100 mg of alpha-GPC itself. That is a lower intake than the doses used in dementia trials, and is best viewed as general cholinergic support rather than a therapeutic dose.
Related research briefs
Alpha-GPC Dosing for Cognitive Performance: Evidence-Based Guidelines
Mitochondrial Energy and Brain Metabolism: Evidence-Based Nutrient Support for Cognitive Function
Focase 2.0 combines L-Tyrosine, Ashwagandha, Alpha-GPC, L-Theanine, Phosphatidylserine, Rhodiola, Omega-3s, methylated B-vitamins, Vitamin D3, Caffeine, and BioPerine at clinically informed doses.
Learn More →Free tool
Compare nootropic labels side by side
Alpha-GPC, L-Theanine, Rhodiola and more — dose by dose against Alpha Brain, Mind Lab Pro, Neuriva.
Free tool · 90 seconds
What’s your Wellness Age?
Twelve lifestyle levers, every adjustment shown, ranked by the years each one is costing you.
This article is part of the Holistic Nutrition Research Library. Browse all research briefs and ingredient factsheets.
References
[1] Kansakar U, Trimarco V, Mone P, Varzideh F, Lombardi A, Santulli G. Choline supplements: an update. Front Endocrinol (Lausanne). 2023;14:1148166.
[2] Secades JJ. Citicoline: pharmacological and clinical review, 2016 update. Rev Neurol. 2016;63(S03):S1-S73.
[3] Wurtman RJ, Regan M, Ulus I, Yu L. Effect of oral CDP-choline on plasma choline and uridine levels in humans. Biochem Pharmacol. 2000;60(7):989-992.
[4] Parnetti L, Amenta F, Gallai V. Choline alphoscerate in cognitive decline and in acute cerebrovascular disease: an analysis of published clinical data. Mech Ageing Dev. 2001;122(16):2041-2055.
[5] Fioravanti M, Yanagi M. Cytidinediphosphocholine (CDP-choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly. Cochrane Database Syst Rev. 2005;(2):CD000269.
[6] McGlade E, Agoston AM, DiMuzio J, et al. The effect of citicoline supplementation on motor speed and attention in adolescent males. J Atten Disord. 2019;23(2):121-134.
[7] Davalos A, Castillo J, Alvarez-Sabin J, et al. Oral citicoline in acute ischemic stroke: an individual patient data pooling analysis of clinical trials. Stroke. 2002;33(12):2850-2857.
[8] Davalos A, Alvarez-Sabin J, Castillo J, et al. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet. 2012;380(9839):349-357.
[9] Ziegenfuss T, Landis J, Hofheins J. Acute supplementation with alpha-glycerylphosphorylcholine augments growth hormone response to, and peak force production during, resistance exercise. J Int Soc Sports Nutr. 2008;5(suppl 1):P15.
[10] Marcus L, Soileau J, Judge LW, Bellar D. Evaluation of the effects of two doses of alpha glycerylphosphorylcholine on physical and psychomotor performance. J Int Soc Sports Nutr. 2017;14:39.
[11] Gatti G, Barzaghi N, Acuto G, Abbiati G, Fossati T, Perucca E. A comparative study of free plasma choline levels following intramuscular administration of L-alpha-glycerylphosphorylcholine and citicoline in normal volunteers. Int J Clin Pharmacol Ther Toxicol. 1992;30(9):331-335.
[12] Sagaro GG, Amenta F. Comparison of the effects of choline alphoscerate and citicoline in patients with dementia disorders: a systematic review and meta-analysis. Front Neurol. 2025;16:1649661.
[13] Tamura Y, Takata K, Matsubara K, Kataoka Y. Alpha-glycerylphosphorylcholine increases motivation in healthy volunteers: a single-blind, randomized, placebo-controlled human study. Nutrients. 2021;13(6):2091.
[14] Lee G, Choi S, Chang J, et al. Association of L-alpha glycerylphosphorylcholine with subsequent stroke risk after 10 years. JAMA Netw Open. 2021;4(11):e2136008.

Leave a comment